

ANNUAL REPORT 2022-2023

TABLE OF CONTENTS

DIRECTORS MESSAGE 2

WHO WE ARE 3


WHAT WE DO 4

ABSPORU 5

HIGHLIGHTED PROJECTS 6

OUR TEAM 12

APPENDIX 29



LAND ACKNOWLEDGEMENT

EPICORE Centre and its team respectfully acknowledges that we are located on Treaty 6 territory, a traditional gathering place for diverse Indigenous peoples including the Cree, Blackfoot, Métis, Nakota Sioux, Iroquois, Dene, Ojibway/ Saulteaux/Anishinaabe, Inuit, and many others whose histories, languages, and cultures continue to influence our vibrant community.

MESSAGE FROM THE DIRECTOR



THANKS FOR READING OUR 2022/2023 ANNUAL REPORT

We pride ourselves in being an accessible part of the critical research infrastructure of the University of Alberta. We provide consultation, expertise, and a robust data management and biostatistics core. We've served 568 individual investigators over the past 30 plus years. That's over 1000 total projects. We've also trained dozens of individuals in research methods.

A few notable things about this past year:


- Welcome to our new postdoctoral research fellow, Dr. Daniel Burton. Dan is working on a randomized trial of home blood pressure monitoring in women whose blood pressure is not within the target range.
- Congratulations to Bo Pan who received his MSc in Statistics and Ariel Qin, who received his MSc in Computing Science
- We continue to be a service partner to the Alberta SPOR Support Unit (AbSPORU) where we provide design/ methods, data management and biostatistics services on their behalf. This relationship has allowed us to provide subsidized research support to many investigators.

I would like to express my appreciation to the EPICORE team – our family, for their dedication, hard work, and wisdom

And finally, a big thank you to the investigators that we serve – we love working with you and appreciate your support. You are why we are here.

All the best,

Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC,
FCAHS, ISHF
Director, EPICORE
Professor and Chair, Department of Pharmacology (until June
30, 2023)
Professor of Medicine (Cardiology), Department of Medicine
Faculty of Medicine and Dentistry
University of Alberta



WHO WE ARE

Open access: A unique aspect of EPICORE Centre is that we are an open group – we provide access to a unique set of skills and services to everyone, rather than the traditional academic approach of only serving ourselves. Such an approach allows a wider range of researchers, regardless of their disciplines or career stage, to access a set of skills and expertise that otherwise might be out of their reach and promote opportunities for collaboration and working together.

EPICORE Centre is an operating unit within the Departments of Medicine and Pharmacology, Faculty of Medicine and Dentistry at the University of Alberta.

EPICORE CENTRE SUPPORTS THE MISSION OF THE DEPARTMENT OF PHARMACOLOGY AND THE DEPARTMENT OF MEDICINE THROUGH:

- Conducting innovative research that makes a difference in health and health care
- Furthering excellence through high quality service to other health researchers
- Educating and training of the next generation of health researchers through graduate student programs, postdoctoral fellowship training and courses
- Partnering with like-minded individuals and organizations

FACULTY OF MEDICINE AND DENTISTRY MISSION:

Our medical school develops diverse, competent and compassionate physician leaders to serve the health needs of Alberta, northern communities and Canada through adaptive innovation and social accountability.

EPICORE MISSION:

To serve the Faculty and our community by generating new knowledge in the areas of health and health care through the design, execution and analysis of clinical trials, health outcomes research and epidemiologic studies

WHAT WE DO

Our Goal is to support clinical and health services research by providing high quality research services to investigators. EPICORE Centre is involved in the full range of activities necessary for the conduct of health research, including protocol/ research design consultations, assistance with grant preparation, case report form design, database creation, data management, biostatistical consultation and analyses.



LONG TRACK RECORD

Celebrating over 25 years of exemplary service



HIGH QUALITY SERVICE

Design/methods, data management and biostatistics



SATISFIED INVESTIGATORS

568 satisfied investigators



HIGHLY SUCCESSFUL

High success rate (3/4 funded, 75%) in helping researchers obtain grants



OUTREACH

986 projects from a variety of health disciplines supported and implemented



BUILDING CAPACITY

Starting residents, graduate students, trainees and early career researchers on the right foot and facilitating research conduct

ALBERTA STRATEGY FOR PATIENT ORIENTED RESEARCH SUPPORT FOR PEOPLE AND PATIENT- ORIENTED RESEARCH AND TRIALS UNIT (AbSPORU)

AbSPORU

EPICORE Centre continues to be a service partner that provides specific services on behalf of AbSPORU.

Those services include; design/methods, data management and biostatistics (see figure below for more details).

01 DESIGN/METHODS SERVICES:

1. Research question refinement
2. Project design
3. Methods consultation
4. Grant review and assistance

02 DATA MANAGEMENT


1. Development of case report forms (data collection sheets)
2. Database development and maintenance
3. Randomization
4. Quality Assurance

03 BIostatISTICS









1. Development of analytical plans
2. Sample size calculation
3. Statistical analysis
4. Clinical event adjudication

AbSPORU
Alberta SPOR SUPPORT Unit

To find out more about the ABSPORU, please visit absporu.ca



A world map that highlights locations where EPICORE Centre provided research services

-  Pharmacy
-  Pediatric Cancer
-  Rheumatology
-  Experimental Medicine
-  Pediatric GI
-  Cancer
-  Faculty of Medicine & Dentistry - Medicine D...
-  Orthopedic Surgery

Highlighted Projects



APPROACH 2.0: HIV, HCV, AND SYPHILIS TESTING THROUGH PHARMACIES

INVESTIGATORS:

Deborah Kelly, Christine Hughes, Tasha Ramsey

OVERVIEW:

Human Immunodeficiency Virus (HIV), hepatitis C (HCV), and syphilis are sexually transmitted and blood-borne infections (STBBI) that affect millions of people worldwide, significantly impacting health outcomes, health services, and health budgets. Creative, varied approaches to STBBI testing are necessary to reach the undiagnosed. Community pharmacists are well positioned to improve access to STBBI testing and link clients with prevention and treatment services. Previously we piloted a pharmacist-testing model for HIV infection, which was associated with high client and pharmacist satisfaction and demonstrated effective linkage to care.

The APPROACH 2.0 study adapts the pharmacy model to incorporate new testing innovations for hepatitis C (HCV) and syphilis, as well as HIV, toward improving health outcomes and health system efficiency through integrating these programs within existing health and community resources infrastructure.

OBJECTIVE:

This study aims to i) implement pharmacy-based STBBI testing programs, ii) evaluate pharmacy-based STBBI testing programs, and iii) impact health care delivery policy.

INTERVENTION:

As part of this scale-up intervention study, we implemented a program of point-of-care testing (POCT) and dried-blood spot testing (DBST) in select pharmacies. Building on findings from the APPROACH pilot study (2017), the research protocol involved developing the testing model and supporting pharmacies with implementation, evaluating the program implementation, and impact on client outcomes, preferences, and testing satisfaction.

Testing is available by appointment or on a walk-in basis during advertised testing hours. Testing options include pharmacist-administered POCT for HIV and/or HCV, and dried blood spot testing for HIV, HCV and syphilis. The pharmacy-based testing model includes pre/post-test counseling, and linkage to care plans to confirmatory testing and follow up care. Client demographics and satisfaction will be explored by surveys collected during the visit. Pharmacists will participate in a post-study focus group to discuss barriers/enablers. Implementation will be assessed qualitatively and quantitatively. A preliminary costing assessment will consider the client, pharmacy, and government perspectives.


CURRENT STATE:

The study launched in December 2022. There are 29 participating pharmacies throughout Newfoundland and Labrador, Alberta, and Nova Scotia. Testing through the APPROACH study will be offered until December 2023. As of June 2023, 144 people have been tested across the three provinces.

IN THE WORDS OF THE INVESTIGATORS

“Our collaboration with the EPICORE team has been invaluable. They helped us develop the databases we needed for data collection in the three provinces. Lily has supported us in keeping our databases running efficiently. She has supported many changes both pre- and post-implementation. We appreciate her responsiveness and thoughtful feedback. The EPICORE team’s expertise, professionalism, and timeliness have made our collaboration a great experience. We look forward to working with the EPICORE team in the future.”

- Dr. Deborah Kelly, Dr. Christine Hughes, Amanda Butt and Javiera Navarrete



WEARABLE CONTINUOUS GLUCOSE SENSOR VERSUS ENHANCED USUAL CARE FOR ADULTS WITH TYPE 2 DIABETES NOT ON INSULIN (iCUDE TRIAL)

INVESTIGATORS:

Darren Lau, Rose Yeung and Donna Manca

OVERVIEW:

iCUDE (isCGM With Education and Feedback for Non-Insulin Dependent Type 2 Diabetes (iCUDE) is a randomized trial of intermittently scanned continuous glucose monitoring (isCGM - or “Flash” glucose monitoring”). This trial is unique in examining adults with type 2 diabetes before they need insulin. Participants are randomized to get isCGM for 6 weeks or to get enhanced usual care, with everybody getting sessions with a certified diabetes educator. isCGM is a powerful new technology and this trial will help us understand its role across the spectrum of type 2 diabetes.

Epicore provided consulting, set up a RedCAP database with an online data entry portal, and has continued to administer it. Their online / emailed patient-reported outcomes have been particularly innovative and important to this trial.




<https://bit.ly/3YyJnP3>

IN THE WORDS OF THE INVESTIGATOR

“EPICORE team members are very supportive of early career investigators like myself. Their staff are knowledgeable, experienced, and great to work with, and have been incredibly enthusiastic about the project. This on-going trial would not be possible without their services and support.”

- Dr. Darren Lau



THE MENTAL HEALTH ASSESSMENT AND PRESCRIBING BY ALBERTA PHARMACISTS (MAP-AP) STUDY

INVESTIGATORS:

Matthew Chow, Daniel Burton, Randy Howden, Yazid N Al Hamarneh

OVERVIEW:

The Mental Health Assessment and Prescribing by Alberta Pharmacists (MAP-AP) Study is a 2-year pilot project in community pharmacy, aimed to draw out meaningful conclusions and understand the potential enhanced patient-care benefits from the Alberta pharmacist practicing at full-scope, in the domain of major depressive disorder and generalized anxiety disorder.



IN THE WORDS OF THE INVESTIGATOR

As the primary investigator, the EPICORE team has worked closely with me to give this study the breath-of-life and guidance needed to navigate this clinical frontier where pharmacists can become more involved --their experience and support at every step of study development has been nothing short of impressive! Recruitment launched seamlessly in March of this year--I look forward to the next phase of the study's journey and the final results of this endeavor!

- Dr. Matthew Chow



PHARMACIST-LED INTERVENTION FOR OPTIMAL HEART FAILURE MEDICATIONS: A PILOT RANDOMIZED CONTROLLED TRIAL (PHARM-OPTIMAL HF)

INVESTIGATORS:

Ricky D. Turgeon, Nathaniel M. Hawkins, Ross Tsuyuki, Sean Virani

OVERVIEW:

Heart failure with reduced ejection fraction (HFrEF) is common and associated with increased mortality and poor quality of life. Medications are the cornerstone of HFrEF management, yet are under-used in patients with HFrEF. Pharmacists have extensive training in evidence-based practice, shared decision-making, patient education, medication management, and clinical assessment as it pertains to evaluating the efficacy and safety of pharmacotherapy. As such, they are ideally suited to address this evidence-to-practice gap and optimize pharmacotherapy in patients with HFrEF.

OBJECTIVE:

To determine the feasibility of conducting and guide the design of a definitive trial of a pharmacist-led, remotely-administered intervention to optimize medications for HFrEF as part of a multidisciplinary HF clinic.

DESIGN:

PHARM Optimal-HF Pilot is a pilot, single-center, parallel-group, allocation-concealed, open-label, randomized controlled trial with a computer-generated 1:1 allocation ratio to usual care or usual care plus pharmacist-led HF medication optimization.

We are recruiting a total of 60 participants (30 per group) from the St. Paul's Hospital (SPH) Heart Function Clinic (HFC) in Vancouver, BC. Given the nature of this study as a pilot RCT, the primary outcomes will focus on feasibility with pre-specified criteria to indicate feasibility or need to alter study procedures for the subsequent definitive trial. Secondary outcomes will include several patient-reported outcome measures, measures of use of HFrEF medication, including the modified optimal medical therapy (OMT) score for HFrEF medications, and clinical HF outcomes using standardized definitions from the Heart Failure Collaboratory and Academic Research Consortium, and echocardiographic parameters. The comparison evaluated in this study will be a pharmacist-led HFrEF medication management intervention plus usual care within a HF clinic, versus usual care in a HF clinic alone


CONCLUSION:

This pilot trial aims to determine the feasibility of an enhanced pharmacist-led, remotely-administered intervention to optimize HFrEF medications integrated into a multidisciplinary HFC. In turn, the results of this pilot trial will provide data to estimate parameters required to design a definitive RCT that will convincingly answer whether a pharmacist-led HFrEF medication optimization intervention can improve patient outcomes, to the point that healthcare payers and guideline committees can make strong recommendations regarding allocation of resources toward clinical pharmacy services and incorporating this approach in the care of patients with HFrEF.

IN THE WORDS OF THE INVESTIGATOR

"The EPICORE team was invaluable in helping to develop the database and data collection processes for our study, including a series of patient-reported outcome measure (PROM) questionnaires that enabled us to make this study truly pragmatic."

- Dr. Ricky D. Turgeon



CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS INCEPTION COHORT (CLASSIC)

INVESTIGATORS:

Walter Maksymowych, Liron Caplan, Atul Deodhar, Lianne Gensler, Ben Vandermeer, Martin Rudwaleit, Robert Landewe, Pedro Machado, Alexandre Sepriano, Joachim Sieper, Desiree van der Heijde, Floris van Gaalen, Miranda van Lunteren

OVERVIEW:

The CLASSIC study is a collaboration between the Spondyloarthritis Research and Treatment Network (SPARTAN) and the Assessment of Spondyloarthritis International Society (ASAS). The project involves gathering approximately 1000 patients (half from North America, half from the rest of the world) referred to a rheumatologist with current undiagnosed back pain of more than 3 months with onset at 45 years of age or younger. The primary purpose of the study is to validate and re-assess the 2009 ASAS classification criteria for Axial Spondyloarthritis (AxSpa) in order to obtain classification criteria that meet thresholds of 75% sensitivity and 90%



EPICORE's primary role in the project was to perform a diagnostic statistical analysis of the data to determine which AxSpa correlated variables (both imaging and clinical) are most important in correctly classifying patients as either AxSpa positive or negative. EPICORE's statistician worked closely with project leaders to come up with models that would satisfy both statistical accuracy and face validity.

IN THE WORDS OF THE INVESTIGATOR


"Working with EPICORE's biostatistician on the CLASSIC project has truly been a godsend for this project. We have generated new insights into the analytical approaches for the study data which have taken us to the forefront of the field internationally."

- Dr. Walter Maksymowych





Meet the **Team**



Meet the Team

DR. ROSS TSUYUKI

POSITIONS:

- Director, EPICORE Centre
- Professor and Chair, Department of Pharmacology, Faculty of Medicine and Dentistry (ending June 30, 2023)
- Professor of Medicine (Cardiology), Faculty of Medicine and Dentistry, University of Alberta
- Editor-in-Chief, Canadian Pharmacists Journal
- President, Hypertension Canada

HOMETOWN: Coquitlam, BC

BACKGROUND:

- BSc(Pharm), University of British Columbia
- Residency, St. Paul's Hospital/University of British Columbia
- PharmD, State University of New York at Buffalo
- Fellowship, Division of Cardiology, McMaster University (Supervisor, Dr. S. Yusuf)
- MSc (Health Research Methods), McMaster University




SKILLS/EXPERTISE:

- Health research methods
- Communicator
- Collaborator
- Educator

WHAT I DO:

- Provide leadership to the Department of Pharmacology (term ending, June 30, 2023)
- Health services research, including pharmacy practice research (focus on evidence generation to advance patient care)
- Provision of support to researchers through EPICORE Centre
- Training the next generation of health researchers



HENRY LEE

POSITIONS:

- Associate Director Operations


HOMETOWN: Edmonton, AB

BACKGROUND:

- Bachelor of Commerce, University of Alberta
- Chartered Professional Accountant (CPA), Chartered Accountant (CA), Certified Management Accountant (CMA)

SKILLS/EXPERTISE:

- Seasoned financial manager with Controllershship experience
- Senior Management roles with public, private, and not-for-profit companies.
- Extensive background and knowledge with scientific research entities.



DR. YAZID N AL HAMARNEH

POSITIONS:

- Assistant Professor, Department of Pharmacology, Faculty of Medicine and Dentistry
- Associate Director, Scientific, EPICORE Centre
- Scientific Officer of Alberta SPOR SUPPORT Unit

HOMETOWN: Madaba, Jordan

BACKGROUND:

- BSc in Pharmacy, the University of Jordan, 2005
- Professional Medical Representative at Merck Sharp and Dohme IA, 2005-2006
- PhD in Clinical Pharmacy and Pharmacy Practice, Queen's University Belfast, 2010
- Postdoctoral Fellowship in Medicine (Cardiology) from the University of Alberta, 2015



SKILLS/EXPERTISE:

- Research methodology and design (quantitative and basic qualitative)
- Grant writing and evaluation
- Basic statistics (analytical plan, sample size calculation and basic statistical analysis)
- Basic REDCap and FunctionPoint
- Conducting pharmacy practice research
- Cardiovascular risk calculation and identification and management of cardiovascular disease risk factors

LILY YUSHKO

POSITION:

- Team Lead, Clinical Research Informatics


HOMETOWN: Kyiv, Ukraine

BACKGROUND:

- MEd, National Pedagogical University, Kyiv, Ukraine
- Computer Systems Technology, NAIT, Edmonton, AB

SKILLS/EXPERTISE:

- Expertise in Systems analysis and design
- Proficiency in all aspects of clinical and research databases development and support
- Fluent knowledge of cross platform data management and integration
- Years of experience in finding out exactly what needs to be done and doing it right



ARIAL XIAO QIN

POSITIONS:

- Clinical Research Informatics Analyst


HOMETOWN: Jiangsu, China

BACKGROUND:

- Bachelor of Computer Engineering, Iowa State University, 2010 - 2014
- Master of Computer Science, University of Alberta, 2021 - 2022

SKILLS/EXPERTISE:

- Full Stack C# .NET Developer in design, analysis and implementation of web applications using Microsoft Technologies
- Skilled in database with SQL Server, Oracle SQL, PL/SQL
- Mobile App development with IOS & Android
- Skilled in Machine Learning, data analysis and visualization with Python



BEN VANDERMEER

POSITIONS:

- Senior Biostatistician, EPICORE centre
- Senior Biostatistician, Alberta Research Centre for Health Evidence (ARCHE)


HOMETOWN: Edmonton, AB

BACKGROUND:

- Bachelor of Science (Statistics), University of Calgary
- Masters of Science (Double Major: Statistics and Pure Mathematics), University of Calgary
- Statistical Methodologist, Statistics Canada
- Star Child Health: Standards Development Group on Data Monitoring Committees and Adequate Sample Size.

SKILLS/EXPERTISE:

- Expertise with all common statistical analysis methods
- Proficiency in meta-analysis and network meta-analysis
- Bayesian Statistical Methods
- Familiarity with many statistical programming software including SAS, R, Stata, StatXact, and WinBUGS.
- Teaching and explaining statistical concepts to non-statisticians
- Interpersonal and communication skills



BO PAN

POSITION:

- Biostatistician


HOMETOWN: Nanjing, China

BACKGROUND:

- Bachelor of Science (Specification in Mathematics), University of Alberta, Fall 2013 – June 2017
- Masters of Science (Statistics), University of Alberta, Fall 2020 – Dec 2022
- Doctor of Philosophy, University of Alberta, Jan 2023 – Current

SKILLS/EXPERTISE:

- Robust Statistics for Stochastic Optimization: Robustness in machine learning and optimization, Distributionally robust approach sample average approximation, and Meta optimization.
- Numerical Algorithms: Convex analysis and monotone operator theory, Damped inertial dynamics system, and Distributed decentralized Learning.
- Statistics for Clinical Trials: determines the most appropriate methodology in carrying out identified research goals, organizes the data and conducts advanced statistical analysis of research results for future replications and/or extensions of the results



DR. KAITLYN WATSON

POSITION:

- CIHR-funded Health System Impact Fellow, EPICORE Centre, UofA; Hypertension Canada; Centre for Implementation, OHRI 2022-24


HOMETOWN: Brisbane, Australia

BACKGROUND:

- Postdoctoral research fellow, EPICORE Centre 2020-22
- PhD in pharmacy practice and disaster health, Queensland University of Technology
- B.Pharm, University of Queensland with 1st Class Honours
- Graduate Certificate in Applied Pharmacy Practice (10797NAT), Pharmaceutical Society of Australia
- Fellow, Higher Education Academy
- Consultant for the World Health Organization Regional Office for Europe, 2020
- Educator, Queensland University of Technology, 2016-2019
- Clinical pharmacist, Greenslopes Private Hospital, 2015-2019

SKILLS/EXPERTISE:

- Implementation scientist
- Pharmacy practice researcher
- Research methodology and design (quantitative and qualitative)
- Ethics approval processes
- Project management
- Communicator
- Educator



DR. STEPHANIE GYSEL

POSITIONS:

- Post-doctoral research fellow, EPICORE Centre, started October 2021
- Founder, Apothecare Pharmacy, Calgary, AB


HOMETOWN: Winnipeg, MB

BACKGROUND:

- BSc in Pharmacy, University of Alberta, 2009
- PharmD, University of Alberta, 2020
- Mini-MBA, Sauder School of Business, UBC, 2022

SKILLS/EXPERTISE:

- Clinical pharmacy practice and patient care
- Development of novel community pharmacy-based clinical programs
- Pharmacy practice researcher
- Collaborator
- Extensive leadership experience
- Strong problem solving and critical thinking skills
- Strong business acumen



DR. DAN BURTON

POSITIONS:

- Post-doctoral research fellow, EPICORE Centre, started December, 2022
- Owner, Apothecare Pharmacy, Calgary, AB
- Founder, Health Evolved, Calgary, AB

HOMETOWN: Prince George, BC

BACKGROUND:

- BSc in Microbiology, University of Alberta, 2012
- BSc in Pharmacy, University of Alberta, 2016
- PharmD, University of Alberta, 2017



SKILLS/EXPERTISE:

- Clinical pharmacy practice and patient care
- Social media marketing
- Certified bariatric educator
- Motivational interviewing and behavioural change clinician
- Pharmacy practice researcher
- Collaborator
- Strong problem solving and critical thinking skills

JONATHAN CHAN

POSITION:

- Research Assistant, EPICORE Centre
- Research Director, Medi-scribe



HOMETOWN: Edmonton, AB

BACKGROUND:

- Doctor of Pharmacy student, University of Alberta, 2020-2024
- Biological Sciences student, University of Alberta, 2018-2020

SKILLS/EXPERTISE:

- Keen to learn new research skills
- Basic knowledge in research design/methodology, quantitative research, qualitative research
- Literature review and writing
- REDCap (research database/data collection)
- Pharmacy software technology startup



PAUL BRACONNIER

POSITIONS:

- Business Consultant

HOMETOWN: Regina, SK

BACKGROUND:


- BBA (Business), University of Regina
- Chartered Accountant (retired)
- Led a full service clinical contract research company that managed and conducted human clinical trials, with operations in Canada, Mexico & Argentina
- Life Sciences-focused TEC Edmonton Executive-In-Residence



SKILLS/EXPERTISE:

- Strong interpersonal and communications skills
- Cross functional team membership and leadership
- Sound business judgment and common sense approach to problem solving
- Customer oriented approach for both internal and external customers
- Team player and team builder, consensus builder
- Extensive financial, legal, administrative and information system management
- Interaction with the investment community including investor and analyst presentations and discussions
- Extensive negotiations of business mergers, divestitures, acquisitions and software licensing agreements

CONFERENCES AND AWARDS



RSAP Journal
@RSAPjournal

Photovoice captured the lived experiences of pharmacists and highlighted their work in responding to the pandemic through various public health and leadership roles.



sciencedirect.com

A photovoice study on community pharmacists' roles and ... Community pharmacists were the face of the health response to the unprecedented COVID-19 pandemic. Thei...

FUN AND REWARDS



CONGRATULATIONS TO BO AND ARIAL ON COMPLETING THEIR MASTER'S



Bo Pan completed his Master's of Science in Statistics



Arial Xiao Qin completed his Multimedia Master's in Computer Science

APPENDICES



50 CURRENT PROJECTS

<https://www.epicore.ualberta.ca/home/appendix-a-2023/>



568 INVESTIGATORS SERVED

<https://www.epicore.ualberta.ca/home/appendix-b-2023/>



30 NEW EPICORE CENTRE PUBLICATIONS

<https://www.epicore.ualberta.ca/home/appendix-c-2023/>

APPENDICES



50 CURRENT PROJECTS

<https://www.epicore.ualberta.ca/home/appendix-a-2023/>

1. Rheum4U (Dr. Dianne Mosher)
2. CHANGE (Dr. Doug Klein)
3. MS Proms RCT (Drs. P. Smyth, Nathan Chu)
4. ON TRAAC (Dr. Keeling, Dr. Katz)
5. BETTER Institute (Dr. Donna Manca)
6. RxPATH (Dr. Kaitlyn Watson)
7. COPD (Dr. Makhinova)
8. Pharmacist Intervention on Lower Urinary Tract Symptoms trial (PILUTS) (Dr. Cheryl Sadowski).
9. QCARxE (Dr. Monica Zolezzi, Qatar)
10. MAP-AP (Matthew Chow)
11. PERK II (Dr. Kevin Hildebrand – ketotifen in elbow surgery)
12. PAUSE (Dr. M James)
13. Food Rx (Dr. Dana Olstad)
14. LiveRx (Dr. Mark Swain)
15. IMPACT survey (Dr. Stephanie Keeling)
16. Hemodialysis project (Dr. Neesh Pannu)
17. Pharmacist testing for TB (Tuberculin skin testing) (Dr. Stephanie Gysel)
18. AWF pilot trial (Dr. Neufeld, Dr. Lam)
19. IGNITE (COVID-19 catalyst study in pharmacy Dr. Yazid Al Hamarneh, Dr. Kaitlyn Watson)
20. EpiRxISK (Dr. Yazid Al Hamarneh)
21. RxING Japan (Dr. Hiroshi Okada):
22. Metformin in Fragile X syndrome (Dr. Francois Bolduc)
23. Quantifying the Loss of Blood Pressure Control in Newfoundland and Labrador—The Other Pandemic (Dr. Tiffany Lee)
24. TBI clinic health system performance study (Dr. Erica Lester)
25. iCUE (glucose flash monitoring, Dr. Darren Lau)
26. HPV awareness and prevention in Dental settings (Dr. Cheryl Cable)
27. INSPIRE worldwide (Kaitlyn Watson)
28. LiveRx Decision aid (Christine Hughes)
29. Evaluation of pediatrics emergency department protocols (Dr. Gaya Narendran):
30. CHANGE-COPD (Dr. Doug Klein)
31. Outcomes and implication of OAT program in remand setting (Dr. Rabia Ahmed and Dr. Nagma Grewal)
32. Reducing Infection EVD/ELD and shunt patients (Dr. Mark Hamilton)
33. Pain relief recall following radiofrequency ablation treatment for low back pain (Rob Burnham, Gail Dodd, Jacob Higham)
34. UCalgary Lev2 Pilot RCT Data (Emily Bishop, Justin Bonhomme)
35. WHISP - women with hypertension implementation science project (Dr. Kaitlyn Watson)
36. ICU sleep study (Leslie LaPierre)
37. CLASSIC study (Dr. Walter Maksymowych)
38. APPROACH study (HIV/Hep C screening Dr. D. Kelly, Memorial University Newfoundland)
39. PHARM Optimal-HF Pilot (Dr. R. Turgeon)
40. Hypertension home BP monitoring (Dr. Ross Tsuyuki)
41. DMARDs use in older adults (Dr. Sanjot Sunner, Dr. E. Yacyshyn):
42. COVID in remand Centres: (Dr. Rabia Ahmed)
43. 155 Biomarkers (Dr. Lesley Mitchell)
44. Adhesive Capsulitis Pilot Study (Dr. Terry De Freitas)
45. Nerve Transfer Systematic Review (Dr. Shawn Dodd)
46. POCT (Dr. Yazid Al Hamarneh)
47. Q methodology (Dr. Kaitlyn Watson)
48. Peas and Beans (Dr. Rhonda Bell)
49. May Measurement Momth (Dr. Stephanie Gysel)
50. HIIT in Youth with CHD (Scott Jamieson)

APPENDICES



568 INVESTIGATORS SERVED

<https://www.epicore.ualberta.ca/home/appendix-b-2023/>

1. Abbasi, M	34. Bedard, E	67. Burnham, R	100. Cooper, E	133. Drummond, J
2. Abdelhay, N	35. Bell, N	68. Burt	101. Copeland, J	134. Drummond, N
3. ABBOTT/Abbie	36. Bell, R	69. Burton, D	102. Coulden, R	135. Dukolow, S
4. Abdul, A	37. Bellerose, D	70. Burton, J	103. Couplan	136. Dumper, J
5. Ackman, M	38. Bello, A	71. Butalia, S	104. Craig, S	137. Dunn, M
6. Addison, O	39. Benzies, K	72. Butcher, K	105. Culos-Reed, N	138. Dunn, S
7. Aghazadeh, H	40. Belmurugiah, N	73. Butler, C	106. Cummings	139. Duong, E
8. Agyapong, V	41. Berchuck, M	74. Cable, C	107. Cuvelier, G	140. Duttchen, K
9. Ahmed, R	42. Beveridge, J	75. Cadili, A	108. Dafoe, W	141. Dziwenka, M
10. Alagiakrishnan, K	43. Bharadia, M	76. Cameron, J	109. Dahlan, R	142. Dyck, J
11. Al Hamarneh, Y	44. Bichel, A	77. Campbell, D	110. Damji, K	143. Dytoc, M
12. Ali, S	45. Billington, E	78. Campbell-Scherer, D	111. Dang, J	144. Dziegielewski, P
13. Allen, M	46. Bishop, E	79. Carbonneau, M	112. Davenport, M	145. El Biale, T
14. Alotaibi, G	47. Bolduc, F	80. Carr, F	113. Davidson, S	146. Elhakim, A
15. Anand, V	48. Bomhof	81. Carrie, A	114. Davis, P	147. Elhossieny, O
16. Anderson, C	49. Bonhomme, J	82. Casey, L	115. Davyduke, T	148. Elliott, C
17. Anderson, E	50. Bosonea, AM	83. Castillo, E	116. Deane	149. Emery, D
18. Anderson, S	51. Boule, N	84. Castro-Codesa, M	117. Defeitas, T	150. Emrick, A
19. Anzarut, A	52. Bowering, C	85. Cervera, C	118. Deng, F	151. Escudar, J
20. Armstrong, P	53. Bowman, M	86. Chan, C	119. Dersch-Mills, D	152. Estabrooks, C
21. Ashton, T	54. Braam, B	87. Chan, K	120. Deschamps, J	153. Eurich, D
22. Awosoga	55. Brandwein, J	88. Chan, Michael	121. Devoe, D	154. Evaschesen, C
23. Badri, P	56. Bratu, I	89. Chan, Ming	122. Dewart, K	155. Everaert, D
24. Bagshaw, S	57. Brennand, E	90. Chao, J	123. Dhaliwal, R	156. Ezekowitz, J
25. Bailey, D	58. Brisbois, T	91. Chari, R	124. Diamant, M	157. Fabreau, G
26. Bakal, J	59. Brockway, M	92. Chow, M	125. Dieleman, L	158. Fairgrieve-Park
27. Baqays, A	60. Broderick, G	93. Chowdhury, R	126. Dillane, D	159. Farooq, S
28. Barber, C	61. Broule, N	94. Chowdhury, T	127. Dodd, G	160. Fedorak, R
29. Beahm, N	62. Brown, N	95. Choy, J	128. Dodd, S	161. Fedorak/Alistair
30. Beard, K	63. Buck	96. Chu, N	129. Dolatabadi, S	162. Ferguson, C
31. Beaulieu, C	64. Buldoc, F	97. Chubaty, A	130. Dong, K	163. Fernandes, C
32. Beaupre, L	65. Bullard, M	98. Collins-Nakai, R	131. Douglas, G	164. Fodor, G
33. Becher, H	66. Bungard, T	99. Colmers, W	132. Douglas, J	165. Fox, R

APPENDICES



INVESTIGATORS SERVED

<https://www.epicore.ualberta.ca/home/appendix-b-2023/>

166. Francis, G	201. Gyenes, G	235. Jacka, M	270. Krick, C	305. MacDonald, G
167. Frank, C	202. Gysel, S	236. Jackson, M	271. Kroeker, K	306. MacDonald, K
168. Freedman, S	203. Hall, J,	237. James, M	272. Kumar, A	307. MacDonald, P
169. Fujiwara	204. Hall, K	238. Jameison, S	273. Kutsogiannis, J	308. MacGillivray, M
170. Fuller, M	205. Hamidi, S	239. Janzen, W	274. Lai, F	309. Mackie, A
171. Fung, C	206. Hamilton, M	240. Jean-Anne	275. Lai, T	310. Madsen, K
172. Galvin, D	207. Hanna, J	241. Jeerakathil, T	276. Lam, G	311. Maier, E
173. Gammel, C	208. Har, B	242. Joffe, M	277. Lam	312. Majumdar, S
174. Garcia, L	209. Haubrich, S	243. Johnson, JA	278. Lam, W	313. Makaroff, C
175. Garneau Lung Lab	210. Haykowsky, M	244. Johnston, B	279. Lamb, C	314. Makhinova, T
176. Garros, D	211. Hazelwood, G	245. Jones, A	280. Lamb, T	315. Makowsky, M
177. Ghamdi, M	212. Hazenbiller, O	246. Jones, B	281. LaPierre, L	316. Maksymowych, W
178. Gibb, R	213. Hildebrand, K	247. Kaba, A	282. Lau, C	317. Malcolm, A
179. Giese-Davis, J	214. Highham, J	248. Kalra, S	283. Lau, D	318. Man, P/Sin, D
180. Gilfoyle, E	215. Hirji, A	249. Kanji, H	284. Lazaurescu, A	319. Manca, D
181. Gill, J	216. Hirota, C	250. Kao, D	285. Lee, A	320. Manhas, K
182. Gillespie, W	217. Ho, C	251. Kaplan, G	286. Lee, K	321. Mann, U
183. Gilmour, L	218. Hong, J	252. Katz, S	287. Lee, M	322. Manns, B
184. Ginn, C	219. Hornberger, L	253. Kassiri, J	288. Lee, N	323. Marin, A
185. Gniadecki, R	220. Hossini, F	254. Kaufman, J	289. Lee, S-Y	324. Marra, C
186. Godziuk, K	221. Houdek, D	255. Kawchuk, G	290. Lee, T	325. Marrie, T
187. Goez, H	222. Houle, S	256. Keeling, S	291. Lehr, E	326. Marsh, R
188. Gonzales	223. Houston, S	257. Kelly, D	292. Leon, H	327. Marshall, D
189. Gouda, P	224. Hsiao, R	258. Kendle, D	293. Lester, E	328. Martin, L
190. Gragasin, F	225. Hudson, A	259. Keshteli, A	294. Leung, B	329. Mason, A
191. Graham, M	226. Hughes, C	260. Keys, E	295. Lewanczuk, R	330. Masterson, T
192. Graham, T	227. Humphries, S	261. Khan, N	296. Li, Suqing	331. May, L
193. Gramlich, L	228. Hunt, I	262. Khani-Hanjani, A	297. Lin, A	332. Mayers, I
194. Green, T	229. Huntsman, R	263. Kimber, S	298. Lindberg, M	333. McAlister, F
195. Grewal, N	230. Huynh, H	264. King-Shier, K	299. Liu, X	334. McBrien, K
196. Grinman, M	231. Hwang, P	265. Kleib, M	300. Logsetty, S	335. McEwan, M
197. Gross, D	232. Ickert, C	266. Klein, D	301. Long, R	336. McFarlane, A
198. Guenther, C	233. Institute of Health Economics	267. Kopolovic, I	302. Lu, C	337. McGhan, S
199. Guerra, G	234. Isaac, DM	268. Koshman, S	303. Lunney	338. McIntosh, C
200. Guirguis, M		269. Kotha, V	304. Ma, M	339. McIntosh, K

APPENDICES



INVESTIGATORS SERVED

<https://www.epicore.ualberta.ca/home/appendix-b-2023/>

340. McKenzie, N	374. Neufeld, A	408. Pharis	442. Sadowski, C	476. Smigorowsky, M
341. McKinnon, G	375. Noel, M	409. Plint, P	443. Sadowski, D	477. Smyth, P
342. McLean, D	376. Norris, C	410. Poon, K	444. Samji, R	478. Solimani, M
343. McMurtry, S	377. Norris, J	411. Poonja, A	445. Samuel, S	479. Somily, A
344. McNeely, M	378. Norton, L	412. Popeski, N	446. Sandhu, R	480. Soo, I
345. McNeil, D	379. Nwoke	413. Potvin, C	447. Sarban, V	481. Spoor, M
346. McNeil, J	380. O'Connell, D	414. Power, C	448. Scantlebury, M	482. Spencer, T
347. Meherali, S	381. Ohinmaa, A	415. Pretorius, V	449. Schlosser, MP	483. Spratlin, J
348. Mehrem, A	382. Okada, H	416. Quan, H	450. Schindel, T	484. Steiner, I
349. Mehta, R	383. Okeke-Iheririka, P	417. Rajesky, A	451. Schultz, K	485. Stewart, D
350. Metz	384. Oliver, M	418. Ramsey, T	452. Schulze, C	486. Stewart, J
351. Michail, K	385. Olmstead, D	419. Rashiq, S	453. Schwartz, I	487. Sun, L
352. Michelakis, E	386. Olson, D	420. Rassekh, R	454. Shanks, M	488. Sunner, S
353. Miciak, G	387. Olstad, D	421. Ravid, N	455. Shapiro, A	489. Sutton, R
354. Minhas, R	388. Osman, M	422. Regan, S	456. Shapiro, J	490. Svenson, L
355. Mitchell, L	389. Oster, R	423. Rehani, M	457. Sharma, A	491. Svystun, O
356. Modi	390. Oudit, G	424. Reid, S	458. Sharpe, H	492. Swain, M
357. Mohydeen, S	391. PACU-RAH	425. Rieger, J	459. Sheldon, S	493. Tandon, P
358. Molzahn, A	392. Padwal, R	426. Riley, N	460. Shiau, G	494. Taylor, J
359. Monument, M	393. Pannu, N	427. Robinson, A	461. Shibata, M	495. Thejeel, B
360. Morgan, A	394. Pantano, A	428. Robinson, J	462. Sharifzadeh-Amin, M	496. Temple, C
361. Morgan, C	395. Papathansoglou, E	429. Robles, M	463. Shiau, G	497. Temple-Oberle, C
362. Morison, N	396. Parent, E	430. Rolfson, D	464. Sia, W	498. Teo, K
363. Morrissey, A	397. Park, E	431. Rolfson, D	465. Siddiqi, Z	499. Thompson, A
364. Mosher, D	398. Parsons, L	432. Romney, J	466. Siffeldeen, J	500. Thomson, A
365. Mosli, M	399. Pasiorowski, A	433. Rosenthal, M	467. Silva, M	501. Tomczak, C
366. Mullen, J	400. Pate	434. Ross, D	468. Simpson, S	502. Tonelli, M
367. Murray, A	401. Patel	435. Rowe, B	469. Sinclair, D	503. Torrible, S
368. Mushahwar, V	402. Paterson, I	436. Rudolf, F	470. Singh, A	504. Toth, E
369. Nanda, A	403. Pauly, R	437. Ruiz, M	471. Singh, G	505. Townsend, D
370. Narendran, G	404. Pearson, G	438. Russell, A	472. Sipione, S	506. Toy, J
371. Narine, K	405. Pehowich, M	439. Ryan, E	473. Sivakumar, L	507. Tredget, T
372. Nee, ANewman, S	406. Pendharkar, S	440. Ryan, L	474. Sivakumaran, S	508. Triska, O
373. Nguyen, V	407. Persad, S	441. Saad, E	475. Slaughter, S	509. Tsui, B

APPENDICES



INVESTIGATORS SERVED

<https://www.epicore.ualberta.ca/home/appendix-b-2023/>

510. Tsuyuki, R	522. Venturato, L	534. Weatherald, J	546. Williams, E	558. Yeaman, S
511. Turgeon, R	523. Vethanayagam, D	535. Webb, C	547. Wilson, K	559. Yeung, R
512. Tworek, K	524. Vliagoftis, H	536. Webber	548. Wilson, M	560. Young, C
513. Tymchak, W	525. Vohra, S	537. Weis, E	549. Wismer, W	561. Yuksel, N
514. Tyrrell, B	526. Wagg, A	538. Wells, H	550. Wong, J	562. Zaidi, D
515. Tyrrell, G	527. Walters, B	539. Welsh, R	551. Wright	563. Zappitelli, M
516. Tyrrell, L	528. Walters, S	540. Whiteford, R	552. Wu, C	564. Zhu, J
517. Urquhart, G	529. Walton, S	541. Whiting, J	553. Wu, Q	565. Zimmermann, G
518. Valtuille, L	530. Wang, S	542. Whittaker, J	554. Wurz, A	566. Zolezzi, M
519. Van Diepen, S	531. Warneke, L	543. Wiebe, S	555. Yacyshyn, E	567. Zuk, D
520. Van Haaften, D	532. Watson, J	544. Wilke, M	556. Yanicki	568. Zygun, D
521. Van Zanten, S	533. Watson, K	545. Wilkinson, G	557. Yavari, M	

APPENDICES



EPICORE CENTRE PUBLICATIONS

<https://www.epicore.ualberta.ca/home/appendix-c-2023/>

1. Watson KE, Lee DH, Nusair MB, Al Hamarneh YN. Impact of the Novel Coronavirus (COVID-19) on Frontline Pharmacists Roles and Services: INSPIRE Worldwide Survey. Pharmacy. In Press
2. Watson KE, Schindel T, Tsuyuki RT, Al Hamarneh YN. A photovoice study on community pharmacists' roles and lived experiences during the COVID-19 pandemic. Research in Social and Administrative Pharmacy. In Press
3. Zolezzi M, Elhakim A, Hejazi T, Kattan L, Mustafa D, Aboelbaha S, Homs S, Al Hamarneh YN. Translating and piloting a cardiovascular risk assessment and management online tool using mobile technology. Saudi Pharmaceutical Journal. In press
4. Chu NY, Watson KE, Al Hamarneh, Y.N. et al. Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial. 2023. BMC Neurol 23, 53.
5. Abu Mehrem, A, Al Hamarneh YN et al. Alberta (AB) Collaborative Quality Improvement Strategies to Improve Outcomes of Preterm Infants 32 – 36 Weeks' Gestation: A Protocol for a Multi-centre, Stepped-Wedge Cluster Randomized Trial (The ABC-QI Trial). CMAJ Open. 2023;11:E397-E403
6. Potvin CA, Green J, Pan B, Al Hamarneh YN, Dillane D. A Prospective Observational Study of the Efficacy of Ketamine for Rescue Analgesia in the Post Anesthesia Recovery Unit. Canadian Journal of Anesthesia. 2023 May;70(5):836-841
7. Smyth P, Watson KE, Al Hamarneh YN, Tsuyuki RT. The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis – a randomized trial. BMC Neurol 22, 275 (2022). <https://doi.org/10.1186/s12883-022-02809-9>
8. Amatto A, Smith A, Pan B, Al Hamarneh YN, Taylor Burnham, Robert Burnham. An assessment of the minimal clinically important difference for the pain disability quality-of-Life Questionnaire-Spine. Interventional Pain Medicine. 2022, 1 (3)100116, ISSN 2772-5944
9. Rasiah J, Freedman S, Macdonald L, Prisnie K, Eltorki M, Finkelstein Y, Hopkin G, Santana MJ, Thull-Freedman J, Stang A, Prebeg M, Gagnon IJ, Steele M, Mater A, Katz L, Greenfield B, Plotnick L, Monga S, Lipman EL, Wright B, Dimitropoulos G, Porter R, Hurley K, Al Hamarneh YN, Newton A. Evaluation of parent and youth experiences in advisory groups as part of a mental healthcare clinical trial: protocol for a mixed-method study. BMJ Open. 2022 Jun 17;12(6):e059689.
10. Goswami S, Rosenthal M, Nair S, Inguva S, Al Hamarneh YN, Tsuyuki RT. Retroactive application of the EPIS framework to promote future implementation success in community pharmacy clinical interventions. Journal of the American Pharmacists Association. 2022, ISSN 1544-3191
11. Campbell DJT, Mitchell C, Hemmelgarn BR, Tonelli M, Faris P, Zhang J, Tsuyuki RT, Fletcher J, Au F, Klarenbach S, Exner DV, Manns BJ; Interdisciplinary Chronic Disease Collaboration. Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial. Circulation. 2023 16;147(20):1505-1514.
12. Campbell DJT, Tonelli M, Hemmelgarn BR, Faris P, Zhang J, Au F, Tsuyuki RT, Mitchell C, Pannu R, Campbell T, Ivers N, Fletcher J, Exner DV, Manns BJ; Interdisciplinary Chronic Disease Collaboration. Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial. Circulation. 2023 16;147(20):1492-1504
13. Tsuyuki RT, Watson KE. Taking primary care pharmacy to the next level. Can Pharm J (Ott). 2023 Feb 15;156(2):52-53.
14. McAlister, Finlay A., et al. "Frequency and Type of Outpatient Visits for Patients With Cardiovascular Ambulatory-Care Sensitive Conditions During the COVID-19 Pandemic and Subsequent Outcomes: A Retrospective Cohort Study." Journal of the American Heart Association 12.3 (2023): e027922.

APPENDICES



EPICORE CENTRE PUBLICATIONS

<https://www.epicore.ualberta.ca/home/appendix-c-2023/>

15. Tsuyuki, Ross T. "The last 10 years of pharmacy practice, as told through CPJ editorials." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 156.1 (2023): 3-7.
16. Paes, Danielle, and Ross T. Tsuyuki. "Improving the vaccination experience for our patients." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 156.1_suppl (2023): 6S-6S.
17. Watson, K.E., Dhaliwal, K., Robertshaw, S., Verdin, N., Benterud, E., Lamont, N., Drall, K.M., McBrien, K., Donald, M., Tsuyuki, R.T. and Campbell, D.J., 2023. Consensus Recommendations for Sick Day Medication Guidance for People With Diabetes, Kidney, or Cardiovascular Disease: A Modified Delphi Process. *American Journal of Kidney Diseases*, 81(5), pp.564-574.
18. McMahon, K.R., Lebel, A., Rassekh, S.R., Schultz, K.R., Blydt-Hansen, T.D., Cuvelier, G.D., Mammen, C., Pinski, M., Carleton, B.C., Tsuyuki, R.T. and Ross, C.J., 2023. Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study. *Pediatric Nephrology*, 38(5), pp.1667-1685.
19. Houle, Sherilyn KD, Nancy M. Waite, and Ross T. Tsuyuki. "Taking our best shot: Pharmacy's vaccination success story." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 155.6 (2022): 293-295.
20. Campbell, Norm RC, Raj Padwal, Ross T. Tsuyuki, Alexander A. Leung, Alan Bell, Janusz Kaczorowski, and Sheldon W. Tobe. "Ups and downs of hypertension control in Canada: critical factors and lessons learned." *Revista Panamericana de Salud Pública* 46 (2023): e141.
21. Watson, Kaitlyn E., Kirnvir Dhaliwal, Ella McMurtry, Teagan Donald, Nicole Lamont, Eleanor Benterud, Janice Y. Kung et al. "Sick day medication guidance for people with diabetes, kidney disease, or cardiovascular disease: a systematic scoping review." *Kidney Medicine* 4, no. 9 (2022): 100491.
22. Gysel, Stephanie C., Kaitlyn E. Watson, and Ross T. Tsuyuki. "Appropriate staffing for pharmacists' full scope of practice." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 155.3 (2022): 136-138.
23. Servito, Maria, Abbas Khani-Hanjani, Kayla-Marie Smith, Ross T. Tsuyuki, and John C. Mullen. "Topical vancomycin and risk of sternal wound infections: a double-blind randomized controlled trial." *The Annals of Thoracic Surgery* 114, no. 5 (2022): 1555-1561.
24. Santarossa, T.M., So, R., Smyth, P., Gustavsen, S. and Tsuyuki, R.T., 2022. Medical cannabis use in Canadians with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, 59, p.103638.
25. Houle, Sherilyn KD, Nancy M. Waite, and Ross T. Tsuyuki. "Taking our best shot: Pharmacy's vaccination success story." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 155.6 (2022): 293-295.
26. Campbell, N.R., Whelton, P.K., Oria, M., Wainford, R.D., Cappuccio, F.P., Ide, N., Neal, B., Cohn, J., Cobb, L.K., Webster, J. and Trieu, K., 2023. 2022 World hypertension league, resolve to save lives and international society of hypertension dietary sodium (salt) global call to action. *Journal of Human Hypertension*, 37(6), pp.428-437.
27. Gastens, V., Kiszio, B., Del Giovane, C., Tsuyuki, R., Paradis, G., Chiolerio, A. and Santschi, V., 2022. Pharmacist interventions to improve hypertension management: protocol for a systematic review of randomised controlled trials. *BMJ open*, 12(5), p.e059399.
28. Gysel, Stephanie, and Ross T. Tsuyuki. "Overcoming stigma in pharmacy practice." *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 155.1 (2022): 4-5.
29. Tsuyuki, R.T., Cloutier, L., Gelfer, M. and Campbell, N.R., 2023. The pharmacist's role in facilitating the accurate measurement of home blood pressure. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 156(4), pp.175-176.
30. Tsuyuki, Ross T., and Yazid N. Al Hamarneh. "Are pharmacists really "well placed"?" *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada* 155.4 (2022): 185-186.



EPICORE CENTRE

362 HERITAGE MEDICAL RESEARCH CENTRE
UNIVERSITY OF ALBERTA
EDMONTON, AB
T6G 2S2
(780) 492-8525 PHONE
(780) 492-6059 FAX
WWW.EPICORE.UALBERTA.CA